-
Views
-
Cite
Cite
H.R. Haynes, M. Ginty, K. Kemp, H. Williams, S.M. Pollard, P. White, N. Scolding, A. Wilkins, K.M. Kurian, P63
LIGAND-ACTIVATED TRANSCRIPTION FACTORS PPARγ AND PPARα EXPRESSION IN HUMAN GLIOMA, Neuro-Oncology, Volume 16, Issue suppl_6, October 2014, Page vi10, https://doi.org/10.1093/neuonc/nou249.49 - Share Icon Share
Abstract
INTRODUCTION: Agonists of the ligand-activated transcription factors PPARγ and PPARα are in routine clinical use for Type 2 diabetes and lipid control. In vitro studies suggest that PPARγ and PPARα exert antiproliferative and anti-invasive effects on gliomas. PPAR may therefore have a role as a diagnostic and prognostic biomarker or drug target in human gliomas. METHOD: 52 brain tumour samples diagnosed 2011-2013 (34 WHO Grade IV, 14 WHO Grade III, 4 WHO Grade II gliomas), banked at the Brain Tumour Bank Southwest UK were analysed for PPARγ and PPARα expression using dot and western blot techniques. mRNA expression was quantified using rt-PCR. The expression of PPARγ and PPARα was compared with survival data and stratified by WHO tumour grade. RESULTS: In our study PPARγ and PPARα protein expression differs with WHO glioma grade. WHO grade III gliomas show a higher expression of both PPARγ and PPARα when compared with WHO grade IV gliomas. CONCLUSION:Our results show for the first time that both PPARγ and PPARα protein expression is significantly increased in WHO grade III gliomas compared to WHO grade IV gliomas. PPARγ and PPARα agonists are in current clinical use and future trials stratified by PPARγ and PPARα expression may reveal a patient cohort with optimum clinical response to these agents.